Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)No longer available

Expanded Access RBS2418 Treatment

Expanded Access to RBS2418 for an Individual Patient With Pancreatic Cancer

Outcome
Outcome unknown
Phase
No phase (not a drug trial)
Status
No longer available
Study type
Expanded access
Sites
0
Sponsor type
Industry
Results posted
No
Last update
21 February 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

Given lack of any therapeutic options such as standard of care chemotherapy for this single patient owing to lack of tolerability and opportunity to enroll in any clinical trial due to extent of disease, patient desires to try compassionate use protocol with RBS2418, an oral immunotherapeutic agent that is currently in clinical trials and is well tolerated by patients. Furthermore, patient's tumor has been shown to express ENPP1, the protein targeted by RBS2418